TS23

TS23 is a first-in-class monoclonal antibody developed as a thrombus (blood clot) dissolving agent. It works by targeting and inactivating alpha-2 antiplasmin (A2-antiplasmin), a protein that inhibits fibrinolysis, thereby promoting the dissolution of blood clots. This mechanism is based on mimicking a rare genetic deficiency that makes blood clots easier to dissolve in certain individuals. Unlike traditional anticoagulants that prevent clot formation but do not dissolve existing clots, TS23 actively dissolves clots and may offer improved safety with less risk of bleeding compared to current therapies. The drug is administered intravenously and is being investigated for acute ischemic stroke and pulmonary embolism, with additional development for myocardial infarction and venous thrombosis[1][2][3][4][5][6][7].

Brand names

Stromab

Other names

TS 23TS23TS-23